Cre‐dependent DREADD (designer receptors exclusively activated by designer drugs) mice

H Zhu, DK Aryal, RHJ Olsen, DJ Urban… - genesis, 2016 - Wiley Online Library
H Zhu, DK Aryal, RHJ Olsen, DJ Urban, A Swearingen, S Forbes, BL Roth
genesis, 2016Wiley Online Library
DREADDs, designer receptors exclusively activated by designer drugs, are engineered G
protein‐coupled receptors (GPCR) which can precisely control GPCR signaling pathways
(for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling
has been successfully applied in a variety of in vivo studies, including in mice, to remotely
control GPCR signaling, for example, in neurons, glia cells, pancreatic β‐cells, or cancer
cells. In order to fully explore the in vivo applications of the DREADD technology, we …
Summary
DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein‐coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β‐cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase‐mediated restricted expression of these pathway‐selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439–446, 2016. © 2016 Wiley Periodicals, Inc.
Wiley Online Library